Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (NCT02032823)
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
🩺 Plain-English Summary (8th-Grade Level)
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Who can join: Review the eligibility criteria below.
Location: Research Site — Anchorage, Alabama
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (698 Sites)
Showing the first 25 of 698 sites.
- Research Site — Anchorage, Alabama
- Research Site — Anchorage, Alaska
- Research Site — Gilbert, Arizona
- Research Site — Fort Smith, Arkansas
- Research Site — Baldwin Park, California
- Research Site — Berkeley, California
- Research Site — Duarte, California
- Research Site — Fontana, California
- Research Site — Fresno, California
- Research Site — Greenbrae, California
- Research Site — Los Angeles, California
- Research Site — Los Angeles, California
- Research Site — Los Angeles, California
- Research Site — Los Angeles, California
- Research Site — Martinez, California
- Research Site — Newport Beach, California
- Research Site — Oakland, California
- Research Site — Palo Alto, California
- Research Site — Paradise, California
- Research Site — Roseville, California
- Research Site — Roseville, California
- Research Site — Sacramento, California
- Research Site — San Francisco, California
- Research Site — San Jose, California
- Research Site — San Leandro, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.